- Release Date: 28/04/25 08:32
- Summary: FDA confirms Proteinuria as Primary Endpoint for US approval
- Price Sensitive: Yes
- Download Document 359.86KB
- Forums
- ASX - By Stock
- DXB
- Ann: FDA confirms Proteinuria as Primary Endpoint for US approval
DXB
dimerix limited
Add to My Watchlist
0.99%
!
50.0¢

Ann: FDA confirms Proteinuria as Primary Endpoint for US approval
Featured News
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
|
|||||
Last
50.0¢ |
Change
-0.005(0.99%) |
Mkt cap ! $297.1M |
Open | High | Low | Value | Volume |
51.0¢ | 51.0¢ | 50.0¢ | $631.8K | 1.254M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
6 | 73433 | 50.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
51.0¢ | 265126 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 2 | 0.535 |
1 | 14387 | 0.530 |
2 | 2807 | 0.520 |
1 | 9000 | 0.515 |
1 | 2750 | 0.510 |
Price($) | Vol. | No. |
---|---|---|
0.485 | 3416 | 1 |
0.490 | 1508 | 1 |
0.495 | 41433 | 2 |
0.500 | 33675 | 2 |
0.505 | 83811 | 2 |
Last trade - 16.10pm 18/06/2025 (20 minute delay) ? |
Featured News
DXB (ASX) Chart |
The Watchlist
MEM
MEMPHASYS LIMITED.
Professor John Aitken, Scientific Director
Professor John Aitken
Scientific Director
Previous Video
Next Video
SPONSORED BY The Market Online